What is Corista?
Corista operates at the intersection of medical diagnostics and software engineering, providing the sophisticated DP3 platform. This digital pathology solution is engineered to optimize image management and refine complex workflows for pathologists and life sciences researchers. By facilitating seamless integration with existing imaging hardware and fostering real-time collaborative environments, Corista addresses critical bottlenecks in diagnostic turnaround times. The company's market position is defined by its commitment to enhancing clinical efficiency through high-fidelity data analysis and robust case management tools, effectively digitizing traditional pathology practices to meet the demands of modern healthcare systems.
How much funding has Corista raised?
Corista has raised a total of $400K across 2 funding rounds:
Debt
$350K
Private Equity
$50K
Debt (2020): $350K with participation from PPP
Private Equity (2026): $50K, investors not publicly disclosed
Key Investors in Corista
PPP
Public-Private Partnership
Undisclosed Investor
A private equity participant providing substantial expansion capital to support long-term strategic growth and market penetration.
What's next for Corista?
Following this substantial expansion capital, Corista is well-positioned to accelerate its product development roadmap and broaden its footprint in the global digital pathology market. The strategic focus will likely shift toward deepening the interoperability of the DP3 platform with emerging AI-driven diagnostic tools and expanding its reach into larger hospital networks and research institutions. As the industry moves toward a more integrated, data-centric model of care, Corista's ability to leverage this financing will be instrumental in maintaining its competitive edge and driving the next phase of innovation in pathology workflow automation.
See full Corista company page
